A randomized clinical trial led through the Alliance for Clinical Trials in Oncology and supported by the National Cancer Institute found that duloxetine did not prevent chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer patients. The study evaluated duloxetine’s preventive efficacy in a setting where it is otherwise established for treating painful neuropathy after onset. The trial reported a negative outcome for the primary prevention objective, with researchers concluding duloxetine failed to reduce the incidence or severity of CIPN in the preventive regimen tested. The result narrows the range of candidate strategies for prophylaxis in CIPN. For oncology practice, the finding reinforces the need to carefully distinguish between post-onset symptom management and true prevention of nerve damage. It also suggests that endpoints and trial designs for CIPN prophylaxis will remain a high-focus area for future studies. The report is relevant for clinical decision-making around supportive-care medication use during chemotherapy regimens.